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The case for surgery in very early disease
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In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a 
questionnaire to 320 Japanese institutions regarding the prognosis and 
clinicopathological proﬁles of patients who underwent the resection for 
primary lung neoplasms in 1994. We compiled the data for 7408 pa-
tients from 303 institutions (94.7%). Among these, 6644 patients with 
non-small cell histology were studied in terms of prognosis. The 5-year 
survival rate of the entire group was 52.6%. The 5-year survival rates 
by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% 
for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 
35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV 
(n = 147). The difference in prognosis between neighboring stages was 
signiﬁcant except for between IB and IIA and between IIIB and IV. The 
5-year survival rates by pathological (p-) stage were as follows: 79.5% 
for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 
42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 
719) and 20.0% for IV (n = 259). The difference in prognosis between 
neighboring stages was signiﬁcant except for between IB and IIA and 
between IIIB and IV. The survival curves of stages IB and IIA were 
almost superimposed in both c- and p-settings. Otherwise, the present 
TNM staging system seemed to well characterize the stage-speciﬁc 
prognosis in non-small cell lung cancer. The T1 descriptor deﬁnition 
and stage grouping for testing was revised as follows. According to the 
greatest tumor diameter, T1 tumors were divided into T1a tumors (< or 
=2.0 cm) and T1b tumors (2.1-3.0 cm). With these descriptors, new IA 
and IB stages were deﬁned as T1a N0 M0, T1b N0 M0, and T2 N0 M0, 
respectively. For 6644 patients with histologically non-small cell lung 
cancers resected in 1994 and reported in the Japanese Lung Cancer 
Registry Study, the survivals and prognostic difference between neigh-
boring stages were studied. The 5-year survival of the entire population 
was 52.6%. In the clinical setting, the 5-year survivals of the new IA, 
new IB stages were 77.5% and 69.3%, respectively. In the pathologic 
setting, they were 83.7% and 76.0%, respectively. For both clinical and 
pathologic settings, differences between all neighboring stages were 
statistically signiﬁcant. Subcategorization of T1 and minor changes 
in stage grouping results in a system with signiﬁcant differences in 
prognosis between neighboring stages. Additionally, the deﬁnition of 
“non-invasive peripheral early cancer” will be reported by Japanese 
collaboration study in this session
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Following the results of a meta-analysis published 15 years ago, which 
showed a 5-year survival beneﬁt of approximately 5% for adjuvant 
chemotherapy in patients with non-small cell lung cancer (NSCLC) 
[1], various large multicentre studies have investigated the beneﬁt of 
adjuvant chemotherapy in this disease. 
The ﬁndings of the above mentioned meta-analysis failed to impact 
clinical practice, not because the absolute gain was too small but be-
cause such an estimate was still imprecise, ranging from 1% detriment 
to a 10% beneﬁt. In addition, the heterogeneity of surgical procedures 
and the difference in the staging modalities strongly limit the applica-
bility of the results of this meta-analysis. 
Recently published results of ﬁve such studies suggest that adjuvant 
chemotherapy improves survival in patients with stage IIIA and II 
disease, but not in stage I disease [2-6].
These conclusions have been further supported by a recent meta-analy-
sis of individual patient data - the Lung Adjuvant Cisplatin Evaluation 
(LACE) - from ﬁve large studies (ALPI, ANITA, IALT, JBR.10 and 
Big Lung Trial [BLT]) [7]. This analysis involved data from 4,584 
patients with resected NSCLC who were randomized to adjuvant 
chemotherapy chemotherapy or no further systemic therapy. In some of 
these studies, adjuvant radiotherapy was used and left to the discretion 
of each participating centre. Adjuvant chemotherapy was associated 
with a signiﬁcant beneﬁt in overall survival; at 5 years, there was a 
5.3% ± 1.6% absolute increase in survival in favor of adjuvant chemo-
therapy compared with no further systemic therapy. The overall beneﬁt 
observed varied with stage; there was a signiﬁcant beneﬁt for patients 
with stage II and stage III disease whereas there was no signiﬁcant ben-
eﬁt for those with stage IB disease and an apparent detrimental effect 
for those with stage IA disease. 
In contrast to the ﬁndings above, a meta-analysis of several Japanese 
studies of post-operative adjuvant chemotherapy reported a survival 
beneﬁt in patients with stage I disease [8]. Of the 2,003 patients stud-
ied, 95% had stage I disease. Patients were randomized to receive an 
oral adjuvant treatment with tegafur in combination with uracil (UFT) 
for 2 years or no further treatment. The overall survival rates at 5- and 
7-years were signiﬁcantly greater in patients who had received adjuvant 
chemotherapy than in those who had received surgery alone (81.8% vs 
76.5% at 5 years, p = 0.011; 77.2% vs 69.5% at 7 years, p = 0.001).
The concept of relatively mild, low-dose continuous adjuvant therapy 
is attractive, but the absence of conﬁrmatory adjuvant UFT studies 
outside Japan strongly limit the applicability of these data in clinical 
practice because of potential pharmacogenomic differences between 
Japanese and non-Japanese patients.
In two of the positive studies for adjuvant chemotherapy [4,6], a com-
bination of cisplatin and weekly vinorelbine prolonged survival. These 
ﬁndings led to the conclusion that cisplatin/vinorelbine is a regimen 
of choice for adjuvant therapies. However, in another adjuvant trial, 
the combination of cisplatin and vinorelbine did not perform signiﬁ-
cantly better than any other combination tested [2]. Moreover, when 
the combination of cisplatin plus a third-generation agent including 
taxanes, vinorelbine and gemcitabine are compared ‘head to head’ in 
the metastatic or locally advanced settings, no signiﬁcant differences in 
overall survival are observed. 
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In the two positive studies described above [4,6], the use of adjuvant 
cisplatin/vinorelbine was associated with signiﬁcant toxicity (severe 
neutropenia [grade 3/4] in > 80% of patients and febrile neutropenia 
in > 8-10% of patients) and only few patients could receive treatment 
as scheduled. Therefore, the schedule of administration of vinorelbine 
of these studies is not routinely used. Nevertheless, it is possible that if 
vinorelbine was given by the more widely used schedule (days 1 and 8 
every 3 weeks) it may have been more active. 
Currently, the available evidence suggests that the best candidates for 
adjuvant therapy are those patients who have undergone lobectomy, 
those who have made a complete recovery from surgery, have no severe 
comorbidities, are aged < 70 years and have a performance status of 0 
or 1. Two further issues that need to be addressed in future research are 
the potential differences in survival between smokers and never smok-
ers, and the effect on prognosis of the absence or presence of vascular 
invasion. It is becoming clear that tumors in non-smokers differ from 
those in smokers in terms of histology and possibly prognosis. This 
could have implications for the risk of recurrence and hence the value 
of adjuvant therapy. Similarly, the presence or absence of vascular in-
vasion may inﬂuence the risk of recurrence and hence whether adjuvant 
therapy is likely to be beneﬁcial. 
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What are the critical questions in the thoracic adjuvant 
radiotherapy: evolution from PORT
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Studies of postoperative irradiation show that it does not improve 
results in patients who have no evidence of metastasis to the hilar or 
mediastinal lymph nodes. In fact, postoperative irradiation might have 
a net deleterious effect on survival according to the post operative 
radiation therapy (PORT) meta analysis. Shields observed that local re-
currence was infrequent in the case of a pathologically complete resec-
tion with no evidence of regional lymph node metastasis, so irradiation 
would accomplish little for such patients. Moreover, radiation therapy 
may place an additional burden on pulmonary function, especially in 
patients who have required pneumonectomy. A meta-analysis reiterated 
the long-recognized potential for adverse effects of radiation therapy 
when rigorous CT-based treatment planning is not done. 
Several retrospective studies have suggested that postoperative ir-
radiation can improve outcome when mediastinal nodal metastases are 
present. An analysis of postoperative radiation therapy in available pro-
spective trials, most of which was not based on CT planning, showed 
neither a detrimental nor a beneﬁcial effect. On the basis of the striking 
improvement in local control of squamous cell carcinoma shown by the 
Lung Cancer Study Group, the Eastern Cooperative Oncology Group 
(ECOG) coordinated a large intergroup trial to compare postoperative 
radiation therapy plus concurrent chemotherapy with cisplatin and 
etoposide to postoperative radiation therapy alone. In initial results for 
373 patients eligible for analysis and a median follow-up of 44 months, 
the median survival was 42 months for patients given only radiation 
and 38 months for those given combined-modality treatment (P = 0.48). 
No signiﬁcant differences were found in failure patterns between the 2 
study groups. Therefore, although postoperative irradiation can clearly 
reduce the risk of local recurrence in patients with mediastinal node 
metastasis, its effect on survival (with or without adjuvant chemothera-
py) is still under investigation. 
Finally, Sawyer and others studied patients with stage IIIA (N2) 
NSCLC using regression tree analysis to identify patients at low, inter-
mediate, and high risk of local recurrence. Numbers of involved lymph 
nodes, locations of mediastinal lymph nodes relative to the location of 
the primary tumor, and T stage were used to identify intermediate- and 
high-risk groups. Excluding the low-risk group, postoperative radiation 
therapy conferred a highly signiﬁcant improvement in local recurrence-
free and overall survival rates. This approach can form the basis for fu-
ture studies of the value of postoperative irradiation and chemotherapy.
Controversy continues regarding the most effective treatment for pa-
tients with marginally resectable NSCLC. A retrospective review of pa-
tients treated at The University of Texas M. D. Anderson Cancer Center 
conﬁrmed the impression that patients with more favorable disease 
are selected for surgical intervention. Two small prospective studies 
provided quite similar results suggesting that induction chemotherapy 
improves survival in patients with resectable NSCLC. Important as-
pects of post-operative radiotherapy are patients selection
(N2 NSCLC and lobectomy patients rather than pneumonectomy 
patients). Those patients with N2 NSCLC who require pneumonectomy 
should be treated by chemoradiotherapy to avoid lung toxicity. Careful 
CT/PET based post-pretaive radiotherapy is essential to target positive 
mediastinal nodes without irradiating residual lung . Now we are able 
to SPECT to ﬁnd the part of the functional lung where irradiation needs 
to be avoided. If there was microscopic positive margin left, post opera-
tive radiotherapy needs to be given with minimal 60 Gy in 30 fractions 
and concurrent cisplatin based chemotherapy. For the negative margin 
and N2 patients, 50 Gy in 25 fractions will be given with conformal ra-
diation therapy technique. The lung heterogeneity correction should be 
considered as well as dose volume histogram. The lung volume needs 
to be lea than 40 % at V20 if post-operative radiotherapy will be given. 
If concurrent chemoradiotherapy is required because of the positive 
margins, V20 should be less than 35% to avoid treatment related pneu-
monitis. These patients with microscopic N2 disease might live long 
enough to manifest cardiac toxicity. Therefore avoidance of the large 
volume cardiac irradiation is also essential among patients who already 
have high risk of cardiovascular disease due to smoking. Because of the 
mediastinal nodal irradiation, not all patients need 4DCT.
